MedPath

Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis

Phase 4
Conditions
Pancreatitis, Acute
Hypertriglyceridemia
Interventions
Device: Aphesis
Registration Number
NCT03342807
Lead Sponsor
Peking Union Medical College Hospital
Brief Summary

To investigate an economical and effective way to reduce the level of serum triglyceride in patients with hypertriglyceridemia-induced acute pancreatitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
220
Inclusion Criteria
  1. Adult aged 18 to 80 years old;
  2. abdominal pain consistent with AP;
  3. serum amylase and / or lipase activity is at least 3 times higher than the normal upper limit;
  4. abdominal imaging consistent with AP imaging changes.
  5. severe hyperlipidemia "fasting serum TG> 1,000 mg/dL (11.2mmol/L)";
  6. except for other AP causes, such as cholelithiasis, alcohol, drugs and so on.
Exclusion Criteria
  1. other etiologies other than hyperlipidemia leading to AP;
  2. fasting serum TG less than 1,000 mg / dL (11.2mmol / L);
  3. acute lipid-induced pancreatitis at the same time combined with other etiologies of acute pancreatitis.
  4. the existence of plasma replacement contraindications: serious allergies to plasma, human serum albumin, heparin and others; the existence of mental disorders; unstable heart or cerebral infarction; intracranial hemorrhage or severe cerebral edema associated with hernia.
  5. without informed consent, the patient refused to plasma replacement, and other circumstances may bring significant bias.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group InsulinInsulin-
Group AphesisAphesis-
Primary Outcome Measures
NameTimeMethod
serum TGevery 4 hours in first 3 days

Elimination of serum triglyceride.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath